Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AlzProtect SAS

This article was originally published in Start Up

Executive Summary

AlzProtect SAS believes that Alzheimer's disease is caused by the loss of neuroprotective factors including APP intracellular domain and sAPP alpha, both of which are produced during the metabolism of amyloid precursor protein. The start-up is developing compounds that can stimulate the APP, increasing the production of neuroprotective compounds.

You may also be interested in...



Cognition Therapeutics Inc.

Using proprietary assays, Cognition Therapeutics Inc. has discovered small-molecule, highly brain-penetrable drugs that block soluble toxic amyloid beta oligomers in their reactive form, rather than target amyloid beta plaque or expression of the monomer building blocks.

Axerion Therapeutics Inc.

Axerion Therapeutics Inc.'s technology aims to block the binding of Amyloid beta to the prion protein PrP-C, a mechanism its scientists say is the toxic trigger behind neuronal death in Alzheimer's disease. Based at Yale University in New Haven, the team found that mice with AB plaques but no PrP-C showed no cognitive impairment. (Also see "Axerion Therapeutics Inc." - Scrip, 1 Jul, 2010.)

Alzheimer's Start-Ups Face A Discovery And Clinical Crossroads

With big Phase III failures heating debate about the amyloid hypothesis, small biotechs must convince investors that their early research is pointed in the right direction, and larger ones must design clinical trials with care. We profile four Alzheimer's-focused start-ups in this issue: AlzProtect, Axerion Therapeutics, Cognition Therapuetics and Galantos Pharma.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel